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Abstract
Tuberous sclerosis complex (TSC), a rare genetic disorder caused
by a mutation in the TSC1 or TSC2 gene, is characterized by the
growth of hamartomas in several organs. This includes the growth of
low-grade brain tumors, known as subependymal giant cell astrocy-
tomas (SEGA). Previous studies have shown differential expression
of genes related to the extracellular matrix in SEGA. Matrix metallo-
proteinases (MMPs), and their tissue inhibitors (TIMPs) are respon-
sible for remodeling the extracellular matrix and are associated with
tumorigenesis. This study aimed to investigate the MMP/TIMP pro-
teolytic system in SEGA and the regulation of MMPs by micro-
RNAs, which are important post-transcriptional regulators of gene
expression. We investigated the expression of MMPs and TIMPs us-
ing previously produced RNA-Sequencing data, real-time quantita-
tive PCR and immunohistochemistry in TSC-SEGA samples and
controls. We found altered expression of several MMPs and TIMPs
in SEGA compared to controls. We identified the lowly expressed
miR-320d in SEGA as a potential regulator of MMPs, which can de-
crease MMP2 expression in human fetal astrocyte cultures. This
study provides evidence of a dysregulated MMP/TIMP proteolytic
system in SEGA of which MMP2 could be rescued by microRNA-
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320d. Therefore, further elucidating microRNA-mediated MMP reg-
ulation may provide insights into SEGA pathogenesis and identify
novel therapeutic targets.
Key Words: Extracellular matrix, Matrix metalloproteinases,
MicroRNA, Subependymal giant cell astrocytoma (SEGA), Tuber-
ous sclerosis complex.
INTRODUCTION
Tuberous sclerosis complex (TSC) is an autosomal
dominantly inherited neurocutaneous disorder affecting ap-
proximately 1 million individuals worldwide (1,2). It is caused
by inactivating mutations in either the TSC1 or the TSC2 gene
(3,4) resulting in constitutive activation of the mammalian tar-
get of rapamycin (mTOR) pathway which can affect cell
growth and proliferation (5–8). Several brain abnormalities
are observed in patients with TSC, including cortical tubers,
subependymal nodules and subependymal giant cell astrocyto-
mas (SEGA) (9–11). SEGA are progressive low-grade tumors
that develop in the first 2 decades of life in children and ado-
lescents with TSC with a prevalence ranging from 5% to 25%
(12–16). They are slow-growing tumors located near the fora-
men of Monro and extended growth can lead to the obstruction
of the cerebrospinal fluid flow and acute hydrocephalus
(16,17). Symptoms associated with growing SEGA include
headaches, photophobia, diplopia, ataxia, or changes in sei-
zure severity (18). SEGA are believed to develop from sube-
pendymal nodules and are characterized by distinctive
cytomegalic cells, which display an immature neuroglial phe-
notype (19–22).
Genetically, there is evidence of second-hit inactiva-
tion of TSC1 or TSC2 in SEGA. However, in 20% of
SEGA these second-hit mutations are not observed, suggest-
ing that additional molecular processes might be involved
in SEGA growth (6,23,24). Several studies have performed
transcriptional profiling of SEGA identifying differential ex-
pression of genes related to the immune system, MAPK
family signaling cascades and extracellular matrix (ECM)
organization (24–26). Dysregulation of ECM organization
has also been seen in TSC cortical tubers with a specific
role for matrix metalloproteinases (MMPs) and their endog-
enous inhibitors (TIMPs), suggesting that the ECM might
play an important role in TSC (27–29). MMPs are calcium-
dependent zinc-containing endopeptidases that are expressed
with a propeptide that needs to be removed for activation
(30). TIMPs are “wedge-like”-shaped molecules with 4 resi-
dues at N-terminal that form a ridge that can noncovalently
bind to the active site of MMPs and thereby inactivate
them (31). The MMP/TIMP proteolytic system is known to
be involved in the degradation of ECM (32), tissue morpho-
genesis (33), cell migration (34), angiogenesis (35), blood-
brain barrier (BBB) dysfunction (36), wound healing and
inflammation (37). Differential expression of MMPs is
found in many pathologies including cancer, where they af-
fect proliferation and the metastasis of tumor cells (38–40).
Several MMP inhibitors exist that can regulate MMP
overactivity. However, the currently available MMP inhibitors
can have a variety of side effects indicating the complexity of
MMP regulation (41). MicroRNAs (miRNAs) are short non-
coding RNAs which are 20–25 nucleotides long and are able
to regulate the expression of protein-coding genes, including
MMPs (42,43). They are involved in many physiological pro-
cesses, such as differentiation, proliferation, and development
(44) and have been implicated in neurological disorders
(45,46). Previous research showed several miRNAs to be dif-
ferentially expressed in TSC cortical tubers and SEGA
(26,28,29,47,48). In particular, miRNAs have been shown to
participate in MMP regulation at the post-transcriptional level
in TSC tuber-derived astroglial cultures and glioma cell lines
(28,49,50).
In our previous SEGA transcriptome study, we identi-
fied differential expression of genes related to several path-
ways including ECM organization, but did not further study
the role of the ECM in SEGA in detail (26). As MMPs and
TIMPs may contribute to TSC pathology and cancer, under-
standing their role in SEGA development could provide new
insights into the SEGA biological behavior and potential new
therapeutic targets. Therefore, in this study we investigated
the expression of MMPs and TIMPs in SEGA. Furthermore,
we identified differentially expressed miRNAs in SEGA com-
pared to control tissue that could regulate the expression of
MMPs and further investigated the role of these miRNAs in
SEGA and their regulation of MMP expression in vitro.
MATERIALS AND METHODS
Subjects
A total of 24 SEGA specimens (male/female: 16/8; age
ranging from 1 to 28 years; ethnicity: Caucasian) were col-
lected from the following hospitals: University Medical Cen-
ters Amsterdam (location Academic Medical Center,
Amsterdam, the Netherlands), the University Medical Center
Utrecht (Utrecht, the Netherlands), University Medical Center
Groningen (Groningen, the Netherlands), Medical University
of Vienna (Vienna, Austria), Children’s Memorial Health In-
stitute (Warsaw, Poland), Anna Meyer Children’s Hospital
(Florence, Italy) (Table 1). Twenty-two of the 24 SEGA sam-
ples included in this study were obtained from patients who
met the clinical diagnostic criteria for TSC, whereas 2 samples
were obtained from patients with no other clinical signs of
TSC. Histological diagnosis was confirmed following the cur-
rent WHO classification guidelines (51) by 2 independent neu-
ropathologists. Additional TSC1/TSC2 mutation analysis was
performed as part of routine clinical care on blood or tumor
sample DNA or was determined using massively parallel se-
quencing as described previously (23,52), if available (Ta-
ble 1). Periventricular brain tissue along the lateral ventricle at
the level of either the caudothalamic groove or hippocampus
plus its associated cortex was obtained from autopsies of
patients (postmortem delay less than 24 hours) who did not
have TSC, epilepsy or brain tumors and served as control tis-
sue (frozen: n¼ 8, male/female: 6/2; age ranging from 3 to
87 years; paraffin: n¼ 4, male/female: 1/3; age ranging from
2 months to 44 years). Specimens were obtained and used in
accordance with the Declaration of Helsinki and this study















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































niversity user on 12 June 2020
was approved by the Medical Ethics Committee of each
institution.
RNA-Sequencing
RNA-Sequencing (RNA-Seq) data sets produced by our
laboratory, were retrieved from the European Genome-
phenome Archive (EGA), which is hosted by the EBI and the
CRG (accession number: EGAS00001003787) (26). Data were
retrieved for 19 SEGA samples and 8 control and processed as
previously described (26). Briefly, sequence reads were
trimmed and filtered using FastQC v0.11.5 (Babraham Institute,
Babraham, Cambridgeshire, UK) and Trimmomatic v0.36.
Paired-end reads were aligned to the human reference genome
(GRCh38) with TopHat2 v2.0.13 and default settings (53). For
the small RNA-Seq data set no mismatches were allowed be-
tween the trimmed reads and the reference genome and small
RNA reads were allowed to align a maximum of 10 times.
Next, the number of reads that mapped to each gene, based on
Gencode v25, was determined using featureCounts from the
SubRead package (54). The count matrix was normalized using
the R package DESeq2 (55). Genes and small RNAs with a
Benjamini-Hochberg adjusted p value < 0.05 were considered
differentially expressed. Differentially expressed genes (DEGs)
related to the ECM organization were identified by overlapping
the ECM organization genelist from the Reactome database
with the DEGs produced from the RNA-Seq data (56,57).
To identify miRNAs that could potentially target all 5
MMP genes with a higher expression in SEGA compared to con-
trol (MMP2, MMP11, MMP14, MMP15, and MMP19), miR-
NAs that had lower expression in SEGA (adjusted p value <
0.05) as compared to control and whose expression patterns
where inversely correlated with MMP expression were selected.
The list of predicted miRNA targets for each of the differentially
expressed miRNAs was retrieved from miRWalk2 (58,59). miR-
NAs that were predicted to target all 5 MMPs (MMP2, MMP11,
MMP14, MMP15, and MMP19), were considered potential reg-
ulators of MMP expression.
RNA Isolation and Real-Time Quantitative PCR
Analysis
For RNA isolation, cell culture or fresh brain material
(12 SEGA samples and 8 control samples) was homogenized
in Qiazol Lysis Reagent (Qiagen Benelux, Venlo, The Nether-
lands). RNA was isolated using the miRNeasy Mini kit (Qia-
gen Benelux, Venlo, The Netherlands) according to
manufacturer’s instructions. The concentration and purity of
RNA were determined at 260/280 nm using a Nanodrop spec-
trophotometer (Thermo Fisher Scientific, Wilmington, DE).
mRNA and miRNA expression was evaluated as described
previously (60). Briefly, 250 ng of RNA were reverse-
transcribed into cDNA using oligo dT primers. Real-time
quantitative PCRs (RT-qPCR) were run according to the man-
ufacturer’s guidelines, on a Roche Lightcycler 480 thermocy-
cler (Roche Applied Science, Basel, Switzerland) using
LightCycler 480 SYBR Green I Master (Roche Applied Sci-
ence, Indianapolis, IN) with the following cycling conditions:
initial denaturation at 95C for 5 minutes, followed by 50
cycles of denaturation at 95C for 10 seconds, 65C for
10 seconds, and 72C for 15 seconds, annealing at 95C for
5 seconds followed by extension on 65C for 1 minute. PCR
primers were designed using Universal Probe library (Probe-
Finder version 2.53 for human, Roche Applied Science) (Ta-
ble 2). Expression of miRNAs was analyzed using TaqMan
microRNA assays (Applied Biosystems, Foster City, CA).
cDNA was generated from 50 ng of RNA using TaqMan
MicroRNA reverse transcription kit (Applied Biosystems).
RT-qPCR was performed on a Lightcycler 480 Real-Time
PCR System (Roche Applied Science). Quantification of the
data was done using the LinRegPCR program in which linear
regression on the Log(fluorescence) per cycle number data is
applied to determine the amplification efficiency per sample
(61). The expression of each specific product was divided by
the geometric mean of the concentration of 2 reference genes
(mRNA: Elongation factor 1-alpha [EF1a] and
glyceraldehyde-3-phosphate dehydrogenase [GAPDH];
TABLE 2. Primer List
























niversity user on 12 June 2020
miRNA: the U6B small nuclear RNA gene [RNU6B] and
RNU44).
Immunohistochemistry
Sections were deparaffinated in xylene (3x) and rinsed
in ethanol (100%, 95%, and 70%). Antigen retrieval was
performed by incubating the sections in 0.1 M sodium citrate
buffer pH 6.0 at 121C for 10 minutes using a pressure cooker.
Sections were washed with phosphate buffered saline ([PBS],
pH 7.4) after which they were blocked with 10% normal goat
serum (NGS) for 30 minutes at room temperature. After re-
moval of NGS, primary antibody (1:200 rabbit polyclonal IgG
anti-MMP2, Abcam, Cambridge, UK; 1:500 mouse monoclo-
nal IgG 3/j anti-MMP14, Merck, Darmstadt, Germany) in
Normal Antibody Diluent (Immunological, Duiven, The Neth-
erlands) was added to the sections and incubated overnight at
4C. After incubation with primary antibodies, sections were
washed in PBS and stained with a polymer-based peroxidase
immunohistochemistry detection kit according to manufac-
turer’s guidelines (PowerVision Peroxidase system, Immuno-
Vision, Brisbane, CA). After washing, sections were stained
with 3,30-diaminobenzidine tetrahydrochloride (50 mg diami-
nobenzidine [DAB], Sigma-Aldrich, Zwijndrecht, the Nether-
lands) and H2O2 in Tris-HCl (0.015% final concentration).
The reaction was stopped by washing with dH2O, the sections
were then counterstained with hematoxylin and dehydrated
with ethanol (70%, 95%, 100%) and xylene (3x) and
coverslipped.
Stainings of MMPs were quantified by measuring the
optical density (OD) of SEGA and control tissue using
ImageJ. For each case, 2-3 representative photographs of peri-
ventricular white matter (wm) (n¼ 4) and when present
nearby gray matter (gm) (n¼ 3) were taken (20x magnifica-
tion). Three OD measurements were taken after hematoxylin-
DAB color deconvolution for each respective picture. Finally,
the mean OD was calculated per case.
In Situ Hybridization
Paraffin slides from SEGA and autopsy controls
(Table 1) were deparaffinated in xylene (3x) and rinsed in eth-
anol (2x 100%, 70%) and dH2O. Sections were pretreated us-
ing a pressure cooker in 0.1 M sodium citrate buffer, pH 6.0, at
121C for 10 minutes. The oligonucleotide probe for miR-
320d (TCCTCUCAACCCAGCTUUT) contained LNA modi-
fication, 2-o-methyl modification and digoxigenin (DIG) label
(RiboTask ApS, Odense, Denmark). Sections were incubated
with the probe (1:750 dilution) in hybridization mix (600 mM
NaCl, 10 mM HEPES, 1 mM EDTA, 5 Denhardts, 50%
formamide) for 1 hour at 56C. Sections were washed with
saline-sodium citrate (SSC) 2 for 2 minutes, SSC 0.5 for
2 minutes, and SSC 0.2 for 1 minute (in agitation). After
washing with sterile PBS, sections were blocked for
15 minutes with 0.02% Tween 20 and 1% NGS. Hybridization
was detected with AP labeled with anti-DIG (Roche Applied
Science, Basel, Switzerland). Nitro-blue tetrazolium chloride/
5-bromo-4-chloro-30-indolyphosphate p-toluidine salt was
used as chromogenic substrate for AP (1:50 diluted in NTM-T
buffer [100 mM Tris, pH 9.5; 100 mM NaCl; 50 mM MgCl2];
0.05% Tween 20). Expression of miR-320d was quantified by
measuring the OD of SEGA and control tissue using ImageJ.
For each case, 2 and 3 representative photographs of periven-
tricular wm (n¼ 9) and when present nearby gm (n¼ 7) were
taken (20x magnification). Three OD measurements were
taken for each respective picture. Finally, the mean OD was
calculated per case.
Cell Culture
As SEGA are thought to originate from neuroglial pre-
cursor cells that undergo an altered/impaired development, we
have chosen to use a glial cell type in a developmental state;
(human fetal astrocyte-enriched cells) to study the role of
miR-320d on MMP expression under basal conditions. Pri-
mary fetal astrocyte-enriched cell cultures were obtained from
fetal brain tissue (n¼ 3, 14–19 weeks of gestation) collected
from medically induced abortions as described previously
(47,48), with appropriate maternal written consent for brain
autopsy. Briefly, blood vessels were removed and the tissue
was cut into smaller fragments. The tissue was enzymatically
digested by incubating at 37C for 30 minutes with trypsin.
The enzymatic reaction was stopped by adding twice the
amount of astrocyte medium (DMEM/F10, 10% FCS, 5% pen-
icillin/streptomycin, and 5% glutamine) and the cell suspen-
sion was passed through a 70-mm cell strainer. After washing
2 times with astrocyte medium, the cells were incubated at
37C, 5% CO2 for 48 hours after which they were thoroughly
washed with PBS. Fresh medium was added twice a week and
cultures reached confluency after 2 and 3 weeks. Secondary
astrocyte cultures for experimental manipulation were estab-
lished by trypsinizing confluent cultures and subplating onto
poly-L-lysine (PLL; 15 mg/mL, Sigma-Aldrich, St. Louis,
MO)-precoated 6- and 12-well plates (Costar; 50 000 cells/
well in a 12-well plate for RNA isolation and RT-qPCR).
Transfection of Cell Cultures
Cells on PLL-coated plates were transfected with mimic
pre-miRNA for hsa-miR-320d (50mM; Applied Biosystems,
Carlsbad, CA) for 24 hours. Cells treated with lipofectamine
without mimic were used as a control. Mimics were delivered
to the cells using Lipofectamine 2000 transfection reagent
(Life Technologies, Grand Island, NY) in a final concentration
of 50 nM.
Statistical Analysis
Statistical analyses were performed with GraphPad
Prism version 5 (GraphPad Software, La Jolla, CA) and IBM
SPSS Statistics 24 (IBM Corp., Armonk, NY) using the non-
parametric Mann-Whitney U test or, for multiple groups, the
nonparametric Kruskal-Wallis test followed by Mann-
Whitney U test. A p value < 0.05 was assumed to indicate a
statistical difference. Correlations were assessed with R or
IBM SPSS Statistics 24, using the Spearman’s rank correlation
test (p< 0.05 and 0.7< r > 0.7 was considered statistically
significant).
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RESULTS
MMP and TIMP Expression in SEGA
RNA-Seq data previously produced by our laboratory
was used to specifically investigate the expression of MMPs
and TIMPs in SEGA (26). In total, 19 surgical SEGA samples
(obtained from 17 TSC patients and 2 patients without any
clinical signs of TSC) and 8 area-matched periventricular con-
trols (autopsy specimens) without a history of other neurologi-
cal diseases were subjected to RNA-Seq (26) (Table 1).
Differential gene expression analysis identified 4621 genes
overexpressed and 4779 underexpressed (adjusted p value <
0.05) in SEGA samples compared to control tissue, of which
133 genes belong to the Reactome-based ECM organization
pathway (Fig. 1A). Furthermore, the gene expression of these
133 genes could be used to separate the control and SEGA
samples (Fig. 1B). Among the 133 genes identified MMP2,
MMP11, MMP14, MMP15, MMP16, MMP17, MMP19,
FIGURE 1. The extracellular matrix (ECM) organization in subependymal giant cell astrocytomas (SEGA). (A) Volcano plot
showing the differentially expressed genes ([DEGs]; adjusted p value < 0.05; light gray) between SEGA and control tissue. A total
of 4621 mRNAs were found to be overexpressed and 4779 underexpressed in SEGA (n ¼ 19) as compared to control tissue (n ¼
8). A total of 133 DEGs were related to the Reactome-based ECM organization pathway (dark gray). Among the 133 genes
MMP2, MMP11, MMP14, MMP15, MMP19, TIMP1, TIMP2 were overexpressed and MMP16, MMP17 and MMP25 were
underexpressed. (B) Heatmap with Z-score hierarchical clustering for the RNA expression data of DEGs related to the Reactome-
based ECM organization pathway in SEGA (n ¼ 19) and control tissue (n ¼ 8). The color scale means the gene expression
standard deviations from the mean, with green for low expression and red for the high expression.
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MMP25, TIMP1 and TIMP2 were differentially expressed
(Fig. 1A, B). Though not present in the ECM organization
pathway, the other 2 TIMPs found in the brain, TIMP3 and
TIMP4, were also among the 9400 DEGs (Table 3). These
MMPs and TIMPs were selected for further validation with
RT-qPCR. Higher expression of MMP2, MMP11, MMP14,
MMP15, MMP19, TIMP1, TIMP2, and TIMP3 was found in
SEGA (n¼ 12) as compared to control tissue (n¼ 8; p< 0.05;
Fig. 2A–H). The expression of MMP17 (Fig. 2I) was lower in
SEGA as compared to control tissue, whereas MMP16,
MMP25, and TIMP4 expression did not change (Fig. 2J–L).
RNA expression of MMPs and TIMPs did not correlate with
the age at epilepsy onset, age at surgery, or size of the tumor
(p> 0.05 and0.7< r> 0.7 for both RT-qPCR and RNA-Seq
data). Furthermore, RNA expression of MMPs and TIMPs was
not associated with the clinical features such as gender, TSC
mutation, epilepsy, or preoperative seizure frequency (Mann-
Whitney U test or, for multiple groups, the nonparametric
Kruskal-Wallis test; p> 0.05 for both RT-qPCR and RNA-
Seq data). MMP19 expression based on the RT-qPCR was
higher in recurrent/regrown SEGA compared to nonrecurrent/
regrown SEGA (Supplementary Data Fig. S1; p¼ 0.0485).
However, RNA-Seq data did not show differences between
recurrent/regrown SEGA and nonrecurrent/regrown SEGA
(p¼ 0.96).
MMP2 and MMP14 Protein Expression
Increased in SEGA
As MMP2 and MMP14 had the most abundant RNA ex-
pression in SEGA compared to controls they were selected for
further analysis at the protein level. To study cellular localiza-
tion and distribution, and to quantify protein expression of
MMP2 and MMP14 in SEGA, immunohistochemistry was
performed on SEGA and periventricular control tissue slides
(Fig. 3A–F). In periventricular control tissue both MMP2 and
TABLE 3. Differentially Expressed MMPs and TIMPs in SEGAs as Compared to Control Tissue
mRNA MMP2 MMP11 MMP14 MMP15 MMP16 MMP17 MMP19 MMP25 TIMP1 TIMP2 TIMP3 TIMP4
BaseMean 7918.05 37.645 10816.6 498.068 402.112 129.329 407.115 32.0523 3772.49 27817.6 7473.16 533.5
Log2 FoldChange 5.26395 2.27464 4.13891 2.16889 1.8413 2.9409 3.71133 1.8555 1.49335 2.10445 1.16444 1.77748
LfcSE 0.69286 0.59681 0.40108 0.39237 0.40482 0.69567 0.4314 0.62099 0.35208 0.31444 0.39523 0.6906
Stat 7.59742 3.81131 10.3194 5.52764 4.5484 4.2274 8.60299 2.9879 4.24149 6.69264 2.94624 2.57382
p Value 3E14 0.00014 5.8E25 3.2E08 5.4E06 2.4E05 7.8E18 0.00281 2.2E05 2.2E11 0.00322 0.01006
Adjusted p value 8.4E13 0.00057 6.5E23 3.2E07 3.2E05 0.00012 3.8E16 0.00802 0.00011 4E10 0.00901 0.02403
Control 1 182.645 0 275.352 117.612 711.21 395.731 16.6041 22.1388 599.132 8743.45 4679.59 253.213
Control 2 453.634 13.9939 2239.02 141.105 928.26 165.594 45.4801 46.6462 3266.4 6040.69 2222.69 198.246
Control 3 42.8228 0 1082.38 47.2527 218.544 160.955 57.5892 270.226 3397.76 6622.76 7322.69 243.647
Control 4 224.35 0 213.81 213.81 2567.23 1075.08 30.1142 76.7911 1017.86 4381.61 3014.43 367.393
Control 5 252.687 19.151 588.894 120.758 808.067 170.231 32.9823 26.0667 691.565 6271.96 3574.86 165.976
Control 6 61.4008 20.4669 467.816 273.38 381.562 251.451 48.2435 58.4769 2150.49 12322.6 4942.76 0
Control 7 96.9527 9.61515 1185.87 118.587 497.584 83.3313 18.429 26.4416 1578.49 10136 4299.57 92.9464
Control 8 26.5541 6.88439 70.8108 63.9265 541.9 518.296 57.0421 21.6366 215.383 10492.8 1072 33.4385
SEGA1 350.288 99.906 10408.7 1214.91 83.8717 3.70022 145.542 0 2070.89 8752.26 29806.5 477.329
SEGA2 19 637.7 35.9809 27384.9 721.305 174.845 38.2298 278.29 12.9307 1977.83 59003.1 4009.06 558.267
SEGA3 326.138 14.7288 25176.8 1391.87 131.507 0 193.579 7.36442 5079.34 36881 25576.6 26.3015
SEGA4 170.591 28.7514 12355.4 1046.55 55.586 0.95838 208.927 17.2508 2749.59 28491.6 8542.03 411.144
SEGA5 3984.96 62.718 17916.6 324.24 427.192 77.51 1091.06 21.8921 3878.46 51157.2 4553.56 186.971
SEGA6 15 097.6 29.4384 12479.7 817.734 711.974 7.63219 390.332 6.54187 3086.67 41390.4 4661.08 757.767
SEGA7 48 776.7 90.7741 20215.5 380.941 216.461 33.3614 443.785 0 3766.74 55441.3 6153.24 2215.04
SEGA8 924.957 28.444 6737.01 243.354 92.7064 189.627 31.6044 4.21393 3188.89 29829.3 6329.32 51.6206
SEGA9 1171.21 8.16435 12124.8 866.163 107.621 5.1955 235.282 27.4619 3664.31 40081.8 6475.81 565.567
SEGA10 215.259 11.5576 1533.54 18.781 85.237 4.33408 1272.78 26.0045 9095.07 6490.29 3561.89 0
SEGA11 1669.2 53.9765 14927.1 1188.5 250.533 99.8056 1758.82 42.7738 3814 39267.4 7084.16 89.6214
SEGA12 31 142.2 17.1046 30274.5 599.319 276.305 3.94722 809.18 7.23657 2407.8 68810.6 1033.51 360.513
SEGA13 5142.81 22.1056 7551.02 466.819 202.852 0 274.37 50.7129 6522.46 16450.5 10090.6 3808.67
SEGA14 7749.68 11.8189 19932.6 424.3 87.4601 11.8189 579.128 0 5109.33 45514.7 9754.17 33.093
SEGA15 444.297 56.1474 9724.48 961.829 69.5739 9.76476 281.957 4.88238 6996.45 18311.4 13725.6 86.6623
SEGA16 13 231 11.3008 16272.1 386.488 479.155 75.7155 305.122 2.26017 2356.22 48061.3 2552.86 1237.44
SEGA17 44 702.6 271.937 21 368.3 243.825 195.06 89.4982 523.794 12.0478 5108.28 57 122.2 16 237 1060.78
SEGA18 4069.25 76.7546 12 831.9 469.336 211.39 20.1324 1323.7 22.6489 9297.37 13 926.6 5554.01 54.1057
SEGA19 13 639.8 14.6952 6709.02 585.136 343.333 0 538.378 50.7652 8770.36 21 080.9 4945.6 1068.74
MMPs, matrix metalloproteinases; SEGA, subependymal giant cell astrocytomas; TIMPs, tissue-inhibitors of metalloproteinases.
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MMP14 were not detected in glial cells in the wm. In nearby
cortex tissue, low immunoreactivity of MMP2 and MMP14
was observed in neurons (Fig. 3A, B). In SEGA, moderate to
high immunoreactivity of MMP2 and MMP14 was found in
giant cells (Fig. 3C, D). The OD of MMP2 and MMP14 was
higher in SEGA as compared to periventricular wm of controls
(Fig. 3F; p< 0.05).
miR-320d as a Predictive Regulator of MMPs Is
Expressed at Lower Levels in SEGA Compared to
Control
To identify miRNAs that target MMP2, MMP11,
MMP14, MMP15, and MMP19, differentially expressed miR-
NAs with a lower expression in SEGA as compared to controls
were evaluated with miRWalk2. Based on small RNA-Seq
data, we found 49 miRNAs with lower expression in SEGA as
compared to controls. Six miRNAs (miR-320d, miR-320b,
miR-320c, miR-625-5p, miR-330-5p, and miR-3200-3p) were
predicted to target all 5 MMPs (MMP2, MMP11, MMP14,
MMP15, and MMP19) with a higher expression in SEGA as
compared to controls (Fig. 4A). Spearman correlations using
the RNA-Seq data were calculated between each miRNA and
their predicted MMP target (Table 4). miR-320d showed the
strongest negative correlation with all 5 MMPs (MMP2: R:
0.484, p¼ 0.010; MMP11: R: 0.459, p¼ 0.016; MMP14:
R: 0.572, p¼ 0.002; MMP15: R: 0.471, p¼ 0.013;
MMP19: R:0.433, p¼ 0.024) and was therefore selected for
further analysis. Using RT-qPCR the lower expression of
miR-320d in SEGA as compared to control samples was vali-
dated (Fig. 4B). To study the downregulation of miR-320d on
a cellular level, in situ hybridization was performed (Fig. 4C).
In control tissue, miR-320d is abundant in glial cells in peri-
ventricular wm and neuronal cells, whereas in SEGA miR-
320d was not detected. The OD of miR-320d was lower in
SEGA as compared to controls (Fig. 4D; p< 0.05).
Regulation of MMP by miR-320d Mimic Trans-
fection in Fetal Astrocytes
To study regulation of MMP2, MMP11, MMP14,
MMP15 and MMP19 by miR-320d, fetal astrocytes were
transfected with miR-320d mimic. RT-qPCR revealed that
transfection with 50 nM miR-320d mimic led to a higher ex-
pression of miR-320d (Fig. 5A; p< 0.05). RNA expression of
MMP2, MMP11, MMP14, MMP15 and MMP19 was deter-
mined 24 hours after miR-320d transfection using RT-qPCR,
and showed a lower expression of MMP2 in miR-320d mimic
transfected cells compared to control (Fig. 5B; p¼ 0.002),
whereas the expression of MMP11, MMP14, MMP15 and
MMP19 did not differ between conditions (Fig. 5C–F).
FIGURE 2. Gene expression MMPs and TIMPs differentially expression in subependymal giant cell astrocytomas (SEGA) compared
to controls. (A–L) Gene expression was studied using RT-qPCR analysis of MMP2 (A), MMP11 (B), MMP14 (C), MMP15 (D),
MMP19 (E), TIMP1 (F), TIMP2 (G), TIMP3 (H), MMP17 (I), MMP16 (J), MMP25 (K), TIMP4 (L) in SEGA (n ¼ 12) and controls
(n ¼ 8). Data are expressed relative to the expression observed in control tissue. *p < 0.05, **p < 0.01, ***p < 0.001, Mann-
Whitney U test.
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FIGURE 3. Protein expression of MMP2, MMP14 in subependymal giant cell astrocytomas (SEGA). (A–D) A moderate to high
immunoreactivity of MMP2 (C) and MMP14 (D) was observed in SEGA, while no to low immunoreactivity was seen in
periventricular white matter (wm) and gray matter (gm) control tissue, respectively (A, B). Insets show a higher magnification of
giant cells (indicated with arrows) in SEGA. Scale bar: 100 mm; insets: 50 mm. (E, F) The optical density per case for the
immunoreactivity of MMP2 (E) and MMP14 (F) in periventricular control tissue (n ¼ 3/4) and SEGA (n ¼ 4). *p < 0.05, **p <
0.01, ***p < 0.001, Mann-Whitney U test.
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FIGURE 4. miR-320d is a predictive regulator of MMPs and is lower expressed in subependymal giant cell astrocytomas (SEGA)
compared to control. (A) Heatmap showing all underexpressed miRNAs in SEGA as compared to controls (adjusted p value
<0.05) predicted to target MMP2, MMP11, MMP14, MMP15, and/or MMP19 (based on miRWalk2). Green boxes indicate
MMP19, MMP15, MMP14, MMP11, and/or MMP2 as predicted target of a specific miRNA. (B) Relative expression of miR-320d in
SEGA (n ¼ 12) as compared to control tissue (n ¼ 8). Data are expressed relative to the expression observed in control tissue. *p
< 0.05, **p < 0.01, ***p < 0.001, Mann-Whitney U test. (C) In situ hybridization of miR-320d in periventricular white matter
(wm) and gray matter (gm) control and SEGA tissue. Giant cells are indicated with arrows. Scale bar: 100 mm. (D) The optical
density per case for the in situ hybridization signal of miR-320d in periventricular control tissue (n ¼ 7/9) and SEGA (n ¼ 8). *p <
0.05, ***p < 0.001, Mann-Whitney U test.













MMP2 0.010; 0.484 0.028; 0.423 0.052; 0.379 0.243; 0.233 0.271; 0.22 0.493; 0.138
MMP11 0.016; 0.459 0.024; 0.432 0.012; 0.477 0.03; 0.419 0.072; 0.351 0.062; 0.363
MMP14 0.002; 0.572 0.024; 0.433 0.007; 0.503 0.019; 0.45 0.044; 0.391 0.061; 0.366
MMP15 0.013; 0.471 0.028; 0.422 0.011; 0.481 <0.001; 0.627 0.024; 0.433 <0.001; 0.644
MMP16 0.074; 0.349 0.315; 0.201 0.058; 0.37 0.021; 0.443 0.06; 0.367 0.004; 0.532
MMP17 0.040; 0.397 0.058; 0.369 0.013; 0.47 0.002; 0.56 0.093; 0.33 <0.001; 0.633
MMP19 0.024; 0.433 0.083; 0.340 0.031; 0.416 0.168; 0.273 0.269; 0.22 0.518; 0.13
MMP25 0.050; 0.380 0.125; 0.302 0.039; 0.399 0.095; 0.328 0.085; 0.337 0.202; 0.254
TIMP1 0.372; 0.179 0.634; 0.096 0.403; 0.168 0.489; 0.139 0.565; 0.116 0.477; 0.143
TIMP2 0.001; 0.590 0.014; 0.467 0.011; 0.483 0.034; 0.41 0.014; 0.466 0.084; 0.338
TIMP3 0.348; 0.188 0.475; 0.143 0.275; 0.218 0.096; 0.327 0.073; 0.351 0.014; 0.467
TIMP4 0.259; 0.225 0.102; 0.321 0.383; 0.175 0.308; 0.204 0.251; 0.229 0.099; 0.324
MMPs, matrix metalloproteinases; TIMPs, tissue-inhibitors of metalloproteinases.
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DISCUSSION
This study provides evidence that the MMP/TIMP pro-
teolytic system is dysregulated in SEGA. We showed higher
expression of MMP2, MMP11, MMP14, MMP15, MMP19,
and their endogenous inhibitors TIMP1, TIMP2 and TIMP3
and lower expression of MMP17 in SEGA as compared to
periventricular control tissue. Furthermore, we identified the
lowly expressed miR-320d in SEGA compared to controls as a
potential MMP regulator that can decrease MMP2 expression
in vitro.
MMP and TIMP Expression in SEGA
Dysregulation of ECM organization in TSC cortical
tubers and SEGA has been suggested by several transcriptome
studies showing differential expression of genes related to the
gene ontology term ECM organization, however the ECM has
not been studied in detail in SEGA (24,26,27,29). In this study,
we identified higher expression of MMP2, MMP11, MMP14,
MMP15, MMP16, MMP17, MMP19, MMP25, TIMP1,
TIMP2 and TIMP3 in SEGA as compared to controls. This
suggests that the dysregulation of the MMP/TIMP proteolytic
system is conserved across TSC pathology and might also af-
fect migration during early brain development in TSC. In our
previous study, we showed higher expression of MMPs and
TIMPs in non-SEGA material of TSC patients. Among others,
higher expression of MMP2, MMP14, TIMP1, TIMP2 and
TIMP3 was observed in cortical tubers of TSC patients as
compared to control cortex. Moreover, increased protein ex-
pression of MMP2 and MMP14 was also observed in tubers of
TSC patients and the expression of MMPs and TIMPs was as-
sociated with neuroinflammation and BBB dysfunction (28).
This indicates that the overexpression of MMPs might not be
SEGA-specific, but it does underlie its relevance in the dys-
functional microenvironment that is present in TSC-related
brain alterations. Multiple studies have shown the presence of
neuroinflammation in TSC cortical tubers and SEGA
(24,26,27,29,62–64). Previously, we have shown that the im-
mune system is among the most represented enriched path-
ways in SEGA (26). Furthermore, upregulation of several
cytokines, including interleukin 33, TNF Superfamily member
8, C-C Motif Chemokine Ligand 3, and C-C Motif Chemokine
Ligand 5 was observed in SEGA compared to controls. More-
over, albumin extravasation, with uptake in astrocytes, has
been reported in cortical tubers and SEGA of TSC patients,
suggesting that alterations in BBB permeability are associated
with the inflammation in TSC brain lesions (62,65). MMPs
can contribute to the inflammatory response by cleaving pro-
peptides of cytokines such as TNFa and IL-1b, thereby acti-
vating them (66–68). In turn, neuroinflammation can increase
the expression and activity of MMPs and infiltrating immune
cells such as leukocytes, which are a major source of MMP9
(69,70). The link between the neuroinflammation and MMPs
in SEGA deserves further investigation.
MMPs are also known to be involved in cancer pathol-
ogy in multiple ways, including intravasation and extravasa-
tion of tumor cells, migration of tumor cells in the brain and
adhesion of metastatic cells to the ECM (38–40). Previous re-
search has shown that higher MMP2 expression can be a pre-
dictor for overall survival of patients with astrocytomas (71).
In another study, it was found that MMP14 and MMP19 had
higher expression in gliomas compared to healthy control tis-
sue, and that coexpression of MMP14 and MMP19 predicted
poor survival in human glioma (72,73). Furthermore, a corre-
lation between higher MMP11 and MMP19 expression and in-
creased WHO-grading of malignant tumors has been
suggested (74). However, SEGA are slow-growing, WHO
grade I tumors that are not associated with poor survival rates,
suggesting that in SEGA the higher MMP expression is most
likely not linked to overall survival (51). Furthermore, in this
study we did not find any correlation with the clinical traits in-
vestigated, including preoperative seizure frequency, duration
of epilepsy, size of the tumor, and tumor recurrence/regrowth.
A previous study found increased expression of TIMP1 and
TIMP2 in grade I brain tumors compared to grade II or III
tumors (75). Furthermore, it has been shown that TIMP2, is
also involved in the activation of pro-MMP2 together with
MMP14 (76,77). We found a higher expression of MMP
inhibitors TIMP1, TIMP2 and TIMP3 in SEGA as compared
to control tissue. The higher expression of TIMPs may act as a
compensatory mechanism for higher MMP expression, which
could explain why the higher expression of MMP2, MMP11,
FIGURE 5. MMP expression after transfection with miR-320d in fetal astrocytes. (A–F) TaqMan PCR of miRNA-320d (A) and RT-
qPCR of MMP2 (B), MMP11 (C), MMP14 (D), MMP15 (E), and MMP19 (F) in fetal astrocytes transfected with miRNA-320d
mimic (miR-320d) for 24 hours (n ¼ 2 biological triplets and 3 technical duplicates). Data are normalized to lipofectamine
(control). **p < 0.01, Mann-Whitney U test.
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MMP14, MMP15, and MMP19 does not lead to metastases
and excessive growth in SEGA. Interestingly, we found that
MMP19 was highly expressed in recurrent/regrown SEGA as
compared to nonrecurrent/regrown SEGA using RT-qPCR
analysis. Previous studies found a correlation between
MMP19 expression and tumor malignance/invasion
(72,74,78). Therefore, MMP19 expression could potentially
be utilized as a biomarker for recurrence/regrowth. However,
our sample size of recurrent/regrown SEGA was small and
this effect was not found in the RNA-Seq data, indicating that
further investigation is required.
miR-320d Is a Predictive Regulator of MMPs and
Is Expressed at Lower Levels in SEGA Compared
to Control
Previous research has shown the importance of miRNAs
in TSC and SEGA (26,29) and their role in regulating MMP
expression (28,79). In this study, we identified 6 miRNAs
(miR-320d, miR-320b, miR-320c, miR-625-5p, miR-330-5p,
and miR-3200-3p) with lower expression in SEGA as com-
pared to controls that could potentially target MMP expres-
sion. Research from Qin et al (49) has shown that
downregulation of miR-320d in gliomas predicted lower sur-
vival rates and increased growth and proliferation. However,
in our study we did not find a correlation between the expres-
sion of miR-320d and the size of tumor or tumor recurrence/
regrowth. Furthermore, Qin et al (49) indicated miR-320d as a
regulator of MMP2, decreasing MMP2 protein expression in
glioma cell lines, inducing cell apoptosis and suppressing cell
growth and migration. In accordance with this study, we found
that miR-320d can target MMP2 in human fetal astrocytes, but
did not affect the expression of MMP11, MMP14, MMP15,
and MMP19. Since the interaction of miR-320d was based on
prediction tools, it could be that these MMPs are not respon-
sive to this miRNA, however, further investigation is needed.
Alternatively, it could be of interest to combine miR-320d
with the other 5 miRNAs predicted to target MMP2, MMP11,
MMP14, MMP15 and MMP19 (miR-320b, miR-625-5p, miR-
320c, miR-330-5p, and miR-3200-3p) to increase the regula-
tory effect on MMP expression.
Taken together, this study provides evidence that both
MMPs and TIMPs are highly expressed in SEGA compared to
control tissue, indicating that the MMP/TIMP proteolytic sys-
tem is dysregulated in SEGA as observed in tubers of TSC
patients. The MMP-targeting miR-320d is downregulated in
SEGA. In human fetal astrocytes, the dysregulation of MMP2
can be normalized by miR-320d. We therefore conclude that
targeting MMPs potentially with miR-320d alone or in combi-
nation with other MMP targeting miRNAs could be of interest
as a therapeutic intervention for TSC patients with SEGA.
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